To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)

• Register: ClinicalTrials.gov
• Last refreshed on: 7 August 2023
• Main ID: NCT03644186
• Date of registration: 14/08/2018
• Prospective Registration: Yes
• Primary sponsor: ETOP IBCSG Partners Foundation
• Public title: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) TOUCH
• Scientific title: Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
• Date of first enrolment: April 16, 2019
• Target sample size: 144
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/ct2/show/NCT03644186
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 2

Countries of recruitment

Belgium, France, Italy, Switzerland

Contacts

• Name: Etienne Brain, MD
• Affiliation: Institut Curie, Paris, France

• Name: Laura Biganzoli, MD
• Affiliation: USL4 Hospital of Prato, Italy

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Histologically confirmed invasive breast cancer, with the following characteristics:

- Early breast cancer with tumor size >1 cm (as measured by at least one of the
required examination methods of clinical examination, mammography and
ultrasonography);

- No clinical evidence of regional lymph node metastasis (via physical and/or
radiological exam) (cN0) OR

- Clinical evidence of cN1 status, defined by nodal involvement limited to
clinically or radiologically detectable metastasis to movable ipsilateral level
I, II axillary lymph node(s)

- No evidence of metastasis (M0).

2. Postmenopausal, defined by women with:

- Prior bilateral surgical oophorectomy; OR

- Amenorrhea and age =60 years; OR

- Age <60 years and amenorrhea for 12 or more consecutive months in the absence of
alternative pathological or physiological cause (including chemotherapy,
tamoxifen, toremifene, ovarian suppression, or hormonally-based contraception)
plus FSH and serum estradiol levels within the laboratory's reference ranges for
postmenopausal women

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

4. Primary tumor must have positive estrogen receptor (ER) =10%

5. Primary tumor must be HER2-positive (by IHC and/or ISH)

6. Baseline LVEF =55% measured by Echocardiography (preferred) or MUGA scan

7. Normal hematologic status:

- Absolute neutrophil count =1500/mm3 (1.5 × 109/L);

- Platelets =100 × 109/L;

- Hemoglobin =9 g/dL (=90 g/L).

8. Normal renal function: serum creatinine =1.5 ULN

9. Normal liver function:

- Serum total bilirubin =1.5 × upper limit of normal (ULN). In the case of known
Gilbert's syndrome, a higher serum total bilirubin (<2 × ULN) is allowed;

- AST or ALT =2.5 × ULN;

- Alkaline phosphatase =2.5 × ULN.

10. Written Informed Consent (IC) must be signed and dated by the patient and the
Investigator prior to randomization.

11. The patient has been informed of and agrees to data transfer and handling, in
accordance with national data protection guidelines.

12. The patient agrees in writing to make tumor (mandatory diagnostic core biopsy and
surgical specimen) available for submission for central pathology review and to
conduct translational studies as part of this protocol.

Exclusion Criteria:

1. Tumor of any size with direct extension to the chest wall and/or to the skin
(ulceration or skin nodules) (T4 according to AJCC 8th edition cancer staging TNM)

2. Inflammatory breast cancer

3. Bilateral invasive breast cancer

4. Received any prior treatment for primary invasive breast cancer

5. Any active tumor of non-breast-cancer histology

6. Any of the following in the previous 6 months: myocardial infarction, severe/unstable
angina pectoris, ongoing cardiac dysrhythmias of NCI CTCAE grade =2, atrial
fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic
congestive heart failure (NYHA functional classification =II), cerebrovascular
accident including transient ischemic attack, or symptomatic pulmonary embolism.

7. Concurrent disease or condition that would make the subject inappropriate for study
participation or any serious medical disorder that would interfere with the subject's
safety

8. Contraindications or known hypersensitivity to any of the trial medications or
excipients

9. Treatment with any investigational agents within 30 days prior to expected start of
trial treatment

10. Any GI disorder that may affect absorption of oral medications, such as malabsorption
syndrome or status post major bowel resection

11. Evidence via physical and/or radiological exam of cN2 or cN3 nodal involvement defined
by: metastasis to ipsilateral level I, II axillary lymph nodes that are clinically
fixed or matted, OR involvement of ipsilateral infraclavicular, internal mammary
and/or supraclavicular lymph node(s)

12. History of extensive disseminated/bilateral or known presence of interstitial fibrosis
or interstitial lung disease, including a history of pneumonitis, hypersensitivity
pneumonitis, interstitial pneumonia, obliterative bronchiolitis, and pulmonary
fibrosis. A history of prior radiation pneumonitis is not considered an exclusion
criterion.



Age minimum: 18 Years
Age maximum: N/A
Gender: Female

Health Condition(s) or Problem(s) studied

HER2-positive Breast Cancer

Breast Cancer

Estrogen Receptor Positive Tumor

Intervention(s)

Drug: Pertuzumab

Drug: Letrozole

Drug: Paclitaxel

Drug: Palbociclib

Drug: Trastuzumab

Primary Outcome(s)

Pathological complete response (pCR) [Time Frame: Assessed within 30 days of the time of breast surgery after completion of a treatment period of up to 16 weeks. If the patient does not undergo surgery, assessment will occur within 30 days after all treatment is stopped.]

Secondary Outcome(s)

Frequency of reported adverse events [Time Frame: From the time informed consent is signed, during treatment and until 30 days after surgery. If there is no surgery, adverse events will be collected until 30 days after treatment stops.]

Objective response [Time Frame: Tumour assessments will be performed by ultrasound and mammography at screening (prior to start of treatment), and before surgery. Tumour measurements by caliper will be assessed at the same time points and at the end of cycle 2 (each cycle is 28 days).]

Pathological complete response (pCR) in the breast [Time Frame: Assessed at the time of breast surgery within 30 days of completion of a treatment period of up to 16 weeks. All patients who are discontinued from treatment for any reason will be documented within 30 days after surgery.]

Rate of breast conserving surgery (BCS) [Time Frame: Assessed at 35 months after randomization of the first patient.]

Secondary ID(s)

IBCSG 55-17

2017-005067-40

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Hoffmann-La Roche

Pfizer